Novartis (NYSE:NVS – Get Free Report) is expected to be releasing its earnings data before the market opens on Friday, January 31st. Analysts expect Novartis to post earnings of $1.80 per share and revenue of $12.86 billion for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
Novartis (NYSE:NVS – Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The business had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same quarter in the prior year, the firm posted $1.74 EPS. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.
Novartis Trading Down 1.5 %
Novartis stock opened at $101.85 on Wednesday. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. Novartis has a 12 month low of $92.35 and a 12 month high of $120.92. The stock’s 50 day simple moving average is $100.10 and its two-hundred day simple moving average is $108.64. The firm has a market cap of $208.19 billion, a PE ratio of 11.83, a P/E/G ratio of 1.42 and a beta of 0.57.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on NVS
Novartis Company Profile
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Further Reading
- Five stocks we like better than Novartis
- Differences Between Momentum Investing and Long Term Investing
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Stock Market Upgrades: What Are They?
- What Does the Future Hold for Eli Lilly?
- When to Sell a Stock for Profit or Loss
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.